Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripasudil (K-321) in Fuchs Endothelial Corneal Dystrophy
NCT05795699Phase 3Completed
- Start
- Mar 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of ripasudil in Fuchs endothelial corneal dystrophy (FECD). Started Mar 2023; status: completed.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial corneal dystrophy (FECD)
Beyond the preview
Go deeper on NCT05795699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795699.